|
Name |
beta-Phellandrene
|
Molecular Formula | C10H16 | |
IUPAC Name* |
3-methylidene-6-propan-2-ylcyclohexene
|
|
SMILES |
CC(C)C1CCC(=C)C=C1
|
|
InChI |
InChI=1S/C10H16/c1-8(2)10-6-4-9(3)5-7-10/h4,6,8,10H,3,5,7H2,1-2H3
|
|
InChIKey |
LFJQCDVYDGGFCH-UHFFFAOYSA-N
|
|
Synonyms |
BETA-PHELLANDRENE; 555-10-2; p-Mentha-1(7),2-diene; 2-p-Menthadiene; 3-Isopropyl-6-methylenecyclohex-1-ene; .beta.-Phellandrene; Cyclohexene, 3-methylene-6-(1-methylethyl)-; 3-Methylene-6-(1-methylethyl)cyclohexene; PHELLANDRENE, BETA; 3-Isopropyl-6-methylene-1-cyclohexene; 4-Isopropyl-1-methylene-2-cyclohexene; 3-methylidene-6-propan-2-ylcyclohexene; beta-Phellandren; CHEBI:48741; 3-methylidene-6-(propan-2-yl)cyclohex-1-ene; NSC-53044; 2KK225M001; b-phellandrene; UNII-2KK225M001; HSDB 4080; beta -phellandrene; EINECS 209-081-9; NSC 53044; Phellandrene, .beta.; Epitope ID:123895; 3-METHYLIDENE-6-PROPAN-2-YL-CYCLOHEXENE; CHEMBL444254; BETA-PHELLANDRENE [HSDB]; DTXSID4052215; .BETA.-PHELLANDRENE [MI]; 3-Isopropyl-6-methylenecyclohexene; HY-N8573; NSC53044; (+/-)-.BETA.-PHELLANDRENE; AKOS016008994; 3-Isopropyl-6-methylene-1-cyclohexene #; 3-Methylene-6-(1-methylethyl)-Cyclohexene; 3-methylene-6-(1-methylethenyl)-cyclohexane; CS-0148637; C19818; EN300-2528048; Q19606727
|
|
CAS | 555-10-2 | |
PubChem CID | 11142 | |
ChEMBL ID | CHEMBL444254 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 136.23 | ALogp: | 3.4 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 1 |
Heavy Atoms: | 10 | QED Weighted: | 0.512 |
Caco-2 Permeability: | -4.382 | MDCK Permeability: | 0.00002850 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.002 |
30% Bioavailability (F30%): | 0.003 |
Blood-Brain-Barrier Penetration (BBB): | 0.969 | Plasma Protein Binding (PPB): | 89.57% |
Volume Distribution (VD): | 2.149 | Fu: | 8.47% |
CYP1A2-inhibitor: | 0.409 | CYP1A2-substrate: | 0.38 |
CYP2C19-inhibitor: | 0.142 | CYP2C19-substrate: | 0.866 |
CYP2C9-inhibitor: | 0.211 | CYP2C9-substrate: | 0.347 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.653 |
CYP3A4-inhibitor: | 0.166 | CYP3A4-substrate: | 0.567 |
Clearance (CL): | 11.289 | Half-life (T1/2): | 0.479 |
hERG Blockers: | 0.031 | Human Hepatotoxicity (H-HT): | 0.269 |
Drug-inuced Liver Injury (DILI): | 0.192 | AMES Toxicity: | 0.024 |
Rat Oral Acute Toxicity: | 0.045 | Maximum Recommended Daily Dose: | 0.83 |
Skin Sensitization: | 0.93 | Carcinogencity: | 0.874 |
Eye Corrosion: | 0.3 | Eye Irritation: | 0.906 |
Respiratory Toxicity: | 0.911 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002234 | 0.511 | D04CSZ | 0.217 | ||||
ENC000196 | 0.421 | D0P4MT | 0.188 | ||||
ENC000872 | 0.400 | D0Z8SF | 0.174 | ||||
ENC002264 | 0.400 | D0D2VS | 0.173 | ||||
ENC001809 | 0.344 | D06PSS | 0.167 | ||||
ENC003463 | 0.344 | D06GIP | 0.167 | ||||
ENC003090 | 0.333 | D0TY5N | 0.164 | ||||
ENC000165 | 0.302 | D03DVJ | 0.160 | ||||
ENC000763 | 0.302 | D01CKY | 0.157 | ||||
ENC000762 | 0.302 | D0A6CQ | 0.156 |